---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Long-term morbidity"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Long-term morbidity. Topics: Dysphagia and nutritional support in early infantile onset, Dysphagia and aspiration across the disease course, Silent aspiration in the NIH NPC1 natural history study, Functional disability by domain in the registry, and 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Dysphagia and nutritional support in early infantile onset

> “Many data were missing in the later follow-up of patients (Table 3) but by order of frequency, neurological manifestations included: swallowing troubles (18 patients, 16 of whom required enteral feeding by nasogastric tube or gastrostomy, all before 3 years of age), limb hypertonia (18 patients), cerebellar signs (16 patients), VSGP (14 patients), seizures (12 patients), neuropathic pain (9 patients), gelastic cataplexy (7 patients).”
> “As for later onset NP-C forms, swallowing troubles were very frequent in EI-NP-C patients, with a need of nutritional support for 88% of untreated patients and 100% of miglustat treated patients, at a similar median age of 2.75 and 2.92 years respectively.”
> “Lower limbs were more severely involved than upper limbs, and medications were poorly efficient using antispastic, antidystonic and antalgic drugs in more than 75% of patients.”

Source: [Freihuber et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10362619/)

<a id="topic-2.2.1.7-2"></a>

### Dysphagia and aspiration across the disease course

> “Dysphagia occurs in most NP-C patients at some point in the disease course, ranging in severity from occasional swallowing difficulties to loss of swallowing function necessitating placement of a nasogastric tube or gastrostomy feeding”

Source: [Walterfang et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3552828/)

<a id="topic-2.2.1.7-3"></a>

### Silent aspiration in the NIH NPC1 natural history study

> “We aimed to characterize aspiration and silent aspiration in the National Institutes of Health (NIH) NPC1 Natural History Study (NCT00344331).”
> “Silent aspiration occurred in 24/130 (18.4%) participants.”
> “Considering aspiration risk, 27/130 (20.8%) had NIH-PAS > 1, including all silent aspirators.”
> “Mean time to silent aspiration was ~ 10 years from neurologic symptom onset, with no difference by neurological disease onset.”
> “Silent aspiration is common in NPC1 and closely linked to advancing neurologic disease severity than to age-of-onset phenotype.”

Source: [Solomon et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13539892/)

<a id="topic-2.2.1.7-4"></a>

### Functional disability by domain in the registry

> “A 6-domain composite disability scale was used to calculate the overall disability score for each neurological form.”
> “Across all with neurological onset, the majority of patients showed moderate to severe impairments in all domains, except for ‘swallowing’ and ‘seizure’.”
> “The composite disability scores were notably higher in patients with early onset neurological signs, particularly in late infantile patients.”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.7-5"></a>

### Chronic liver disease, fibrosis, and hepatocellular carcinoma after neonatal liver disease

> “Higher liver stiffness measurement scores, suggesting increased risk for liver fibrosis, were associated with a history of significant liver disease in infancy (p = 0.001).”
> “In addition, individuals who had severe liver disease at birth are at higher risk for developing clinically significant liver disease after the neonatal period.”
> “Given multiple reports of hepatocellular carcinoma in individuals with NPC1, those with a history of severe liver disease should be closely monitored.”

Source: [Agrawal et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12818573/)

<a id="topic-2.2.1.7-6"></a>

### Gastrointestinal, liver, and other comorbidities in the 2025 guideline

> “NPC has the highest early onset penetrance of Crohn's among monogenic diseases due to patients' predisposition to intestinal inflammation.”
> “Although rare in childhood, patients with NPC might have an increased risk of hepatocellular carcinoma (HCC).”
> “Individuals with NPC are at increased risk of hypersalivation/drooling.”
> “There is an increased prevalence of behavioral problems and other psychiatric disorders, such as anxiety, depression, or psychosis, in NPC.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.7-7"></a>

### Progressive dementia and death from aspiration pneumonia in childhood-onset disease

> “Although cognitive impairment may be subtle at first, it eventually becomes apparent that affected individuals have progressive dementia.”
> “Seizures usually improve if the child's survival is prolonged; this improvement presumably reflects continued neuronal loss.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
